Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Free Report)’s stock price was up 1.4% during mid-day trading on Friday . The stock traded as high as $0.85 and last traded at $0.82. Approximately 33,205 shares traded hands during trading, a decline of 37% from the average daily volume of 52,627 shares. The stock had previously closed at $0.81.
Cyclo Therapeutics Trading Up 1.4 %
The business has a 50-day moving average of $0.67 and a 200-day moving average of $0.81.
Cyclo Therapeutics Company Profile
Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.
Read More
- Five stocks we like better than Cyclo Therapeutics
- Why Are Stock Sectors Important to Successful Investing?
- MP Materials: Rare Earth Elements Powering the EV Boom
- How to Invest in Blue Chip Stocks
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- The How and Why of Investing in Gold Stocks
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
